Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 598 clinical trials
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors.

  • 25 Jan, 2021
  • 3 locations
Phase I Study of MOv18 IgE a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours

This first in human study of the new therapeutic antibody MOv18 IgE in patients with advanced cancer seeks to demonstrate the potential for the use of this IgE antibody as an example of the use of the IgE class of antibodies for the treatment of cancer.

  • 27 Jan, 2021
  • 4 locations
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have …

bladder cancer
gilbert's disease
progressive disease
  • 26 Jan, 2021
  • 12 locations
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies

This is a Phase 1/2a, dose-escalation, multicenter, first-in-human, consecutive-cohort, open-label study of BI-1808, as a single agent and in combination with pembrolizumab in subjects with advanced malignancies, whose disease has progressed after standard therapy. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors …

  • 03 May, 2021
  • 8 locations
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination …

intraperitoneal chemotherapy
peritoneal cancer
  • 08 Nov, 2020
  • 1 location
Lymphadenectomy in Early Ovarian Cancer

To assess the impact of comprehensive staging surgery with no lymphadenectomy on survival and quality of life in patients with early-stage ovarian cancer.

  • 30 Jan, 2021
  • 1 location
Risk-Reducing Surgeries for Hereditary Ovarian Cancer

Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese

  • 21 Jan, 2021
  • 1 location
Platino-resistance in Ovarian Cancer

Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive

ovarian cancer
  • 25 Jan, 2021
  • 1 location
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer

This is a large, prospective, single-arm cohort study of transvaginal ultrasonographic screening for ovarian cancer in intermediate to high-risk women from Kentucky. Detection of ovarian

cancer of the ovary
breast cancer
  • 25 Jan, 2021
  • 1 location
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

fallopian tube
intraperitoneal chemotherapy
cytoreductive surgery
ovarian epithelial carcinoma
cancer of the ovary
  • 12 Jun, 2021
  • 1 location